An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Inclusion Criteria:

• Participation in and completion of stipulated final follow-up periods for study NTI 0302, NTI 0303, or other designated studies.

• Have a Karnofsky Performance of > 50 at Baseline

• Capable of self-administration of subcutaneous injections twice daily or availabilityof assistance from caregiver.

• Ability to provide written informed consent or, if unable to provide, have a legalguardian or representative provide written informed consent.

• For women of childbearing potential: a negative serum pregnancy test at Baseline

Exclusion Criteria:

• Concurrent enrollment in any investigational drug or device study, other than NTI 0302, NTI 0303, or other designated studies.

• Systemic steroid use for any indication other than peritumoral brain edema.

• Use or intended use of dexamethasone as an anti-emetic during study.

• Clinical signs and symptoms of cerebral herniation.

• Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrinemetabolic disease which could put the patient at unusual risk during studyparticipation.

• Confounding previous or concurrent neurological disorders that would interfere withadequate clinical evaluation.

• Clinically significant head injury or chronic seizure disorder, if the conditionresults in functional impairment or is likely to interfere withevaluations.(Maintenance anticonvulsant therapy is allowed)

• Central nervous system (CNS) infection.

• Pregnancy, breastfeeding and/or refusal to practice birth control while in study, forwomen of childbearing potential.